NEW YORK (GenomeWeb) – Exact Sciences today announced a year-over-year tumble in its first quarter revenues as it awaits a decision by the US Food and Drug Administration on the company's colorectal cancer screening test.

The Madison, Wis.-based molecular diagnostics firm reported $294,000 in revenues for the three months ended March 31, down 71 percent from $1.0 million for the first quarter in 2013. The figure fell short of the consensus analyst revenue estimate of $600,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.